Results 161 to 170 of about 65,232 (224)

Molecular and genomic advances in breast cancer: A comprehensive review of predictive and therapeutic innovations

Precision Medical Sciences, Volume 15, Issue 3, Page 164-175, September 2026.
Breast cancer subtypes, estrogen receptor‐positive (ER+), HER2‐enriched, and TNBC, are defined by genomic and epigenetic signatures. Multi‐omics profiling, immunotherapy, liquid biopsy, and AI‐driven radiogenomics enable precision medicine. Tools like Oncotype DX and PAM50 support personalized care.
Samina Malik, Arif Malik, Shahzad Ahmad, Hassan Mohsin, Shazia Iqbal   +4 more
wiley   +1 more source

Germline BRCA2 Pathogenic Variant in Metaplastic Breast Carcinoma with Heterologous Mesenchymal Differentiation: A Case Report and Literature Review. [PDF]

Reports (MDPI)
Arduini A, Polati R, Bonisoli GL, Sina S.   +3 more
europepmc   +1 more source

Information Discrimination and Its Implications on Distributing Healthcare Costs Fairly

Bioethics, Volume 40, Issue 7, Page 724-733, September 2026.
ABSTRACT When healthcare resources are scarce, they ought to be distributed fairly across society. For some theories of distribution, an assessment of individual health risk is required for a fair distribution of both healthcare resources and burdens. Despite this requirement, prevailing theories underappreciate the cost of information on health risk ...
Harisan U. Nasir
wiley   +1 more source

Shaping CDK4/6 Inhibitor Resistance: BRCA2 Germline Alterations Bias toward RB1 Inactivation. [PDF]

Cancer Res
Napolitano F, Hanker AB.
europepmc   +1 more source

Discovery of ERα‐Targeting Phytochemicals With In Vitro Cytotoxicity and Computational Prediction of Y537S Mutant Inhibition

Chemical Biology &Drug Design, Volume 108, Issue 3, September 2026.
Integrating high‐throughput virtual screening, cytotoxicity assays, and molecular dynamics simulations, this study identifies the phytochemical ibs‐04156 as a reliable dual‐action candidate across both wild‐type and mutated estrogen receptor alpha (ERα), while ibs‐18821 emerges as a potent allosteric inhibitor specifically targeting the drug‐resistant ...
Dejun Jiang, Oh Wook Kwon, Hanbin Joe, Euijeong Shin, Sungjoon Cho, Hyuk‐Ku Kwon, Youngjin Choi   +6 more
wiley   +1 more source

Monoallelic BRCA1/2 variants in pediatric, adolescent, and young adult patients with central nervous system tumors. [PDF]

ESMO Open
Cipri S, Agolini E, Baldo GD, Cacchione A, Megaro G, Rossi S, Barresi S, Carai A, Colafati GS, Boccuto L, Mastronuzzi A.   +10 more
europepmc   +1 more source

The WHO Classification of Genetic Tumour Syndromes: Considerations for Genetics

Clinical Genetics, Volume 110, Issue 3, Page 389-401, September 2026.
The WHO Classification of Tumours underpins the diagnosis of neoplastic conditions. The new WHO classification of genetic tumour syndromes (GTS) provides international standards for their diagnosis. This diagram highlights the chromosomal distribution of the genes involved in the GTS covered in this classification.
Ian A. Cree, Mark J. Arends, Joseph D. Khoury, Erika R. E. Denton, Anthony J. Gill, Alexander J. Lazar, Ian M. Frayling, Stefan M. Pfister, Mark A. Rubin, Katia R. M. Leite, Raymond Dalgleish, Elspeth A. Bruford, Sharon E. Plon, Ada Hamosh, Michael Francis Walsh, Gabrielle Goldman‐Lévy, Harshima Wijesinghe, William D. Foulkes, Dilani Lokuhetty   +18 more
wiley   +1 more source

Gastric Epithelium from BRCA1 and BRCA2 Carriers Harbors Increased Double-Stranded DNA Damage and Enhanced Growth Potential. [PDF]

Mol Cancer Res
Buckley KH, Dungan ME, Dinh K, Kelly GM, Hausler R, Bennett KE, Clay DG, Youngman JE, Majer AD, Beyries KA, Niccum BA, Shaffer SM, Karakasheva TA, Hamilton KE, Kochman ML, Ginsberg GG, Ahmad N, Maxwell KN, Katona BW.   +18 more
europepmc   +1 more source

When to consider an inborn error of immunity: clues for physicians

Internal Medicine Journal, Volume 56, Issue 9, Page 1488-1499, September 2026.
Abstract The term inborn errors of immunity (IEIs) refers to the rapidly expanding group of genetic disorders causing dysregulation of the immune system. With improved genetic testing in recent years, the number of defined IEIs and their range of phenotypic presentations has grown vastly, with more than 550 IEIs now described.
Meera Thangarajah, Lucinda J. Berglund
wiley   +1 more source

Combination of PARP inhibitor olaparib and a vascular disrupting agent reduces tumor growth in a preclinical model of prostate cancer. [PDF]

Cancer Chemother Pharmacol
Sereti E, Evans-Axelsson S, Törnell J, Rehnmark S, Högberg M, Bjartell A.   +5 more
europepmc   +1 more source